They found that 6-MSITC reduces the production of proinflammatory cytokines, such as IL-6 and TNF-α, and lowers the adhesion of immune cells to endothelial cells, which are crucial factors in the development and progression of inflammation and cytokine storms in patients with COVID-19 [137]. This evidence concerns the gene IL6 and COVID-19.